- Conditions
- Alzheimer's Disease
- Interventions
- LY450139, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 1,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 3,253
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Healthy Participants Study
- Interventions
- PRX019, Placebo
- Drug
- Lead sponsor
- Prothena Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Los Alamitos, California
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Interventions
- Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 9
- States / cities
- Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
- Conditions
- Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
- Interventions
- AMX0035, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Parkinson Disease, Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa, Placebo
- Drug
- Lead sponsor
- William Ondo, MD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Kidney Injury, Adverse Drug Event
- Interventions
- Melatonin, Placebo Capsule
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Somerville, New Jersey
- Conditions
- Thermal Hyperalgesia, Anxiety, Pain
- Interventions
- Ketamine, Placebo, Normal Saline
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Healthy Participants
- Interventions
- Alpha-cyclodextrin, Placebo, Triolein radiolabeled with 100 microcuries of 3^Hydrogen, Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
- Dietary Supplement · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- SAR442168, Placebo, Locally approved intravenous contrast medium for contrast enhanced magnetic resonance imaging (MRI)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 9
- States / cities
- Cullman, Alabama • Maitland, Florida • Sunrise, Florida + 6 more
- Conditions
- Necrotizing Enterocolitis
- Interventions
- hydrocortisone, placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 0 Days to 6 Months
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Hypoglycemia, Healthy
- Interventions
- Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
- Interventions
- Intravenous immunoglobulin, 0.9% Sodium Chloride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Cancers
- Interventions
- Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests
- Drug · Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin (SAR439954), Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 56
- States / cities
- Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
- Conditions
- Common Variable Immunodeficiency, Interstitial Lung Disease Due to Systemic Disease
- Interventions
- Fisetin, Placebo
- Drug
- Lead sponsor
- Avni Joshi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non Small Cell Lung Cancer (Stage III)
- Interventions
- Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 5
- States / cities
- Duarte, California • Atlanta, Georgia • Florham Park, New Jersey + 2 more
- Conditions
- Septic Shock
- Interventions
- Vitamin C, Normal saline
- Drug
- Lead sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Herpes Simplex
- Interventions
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
- Conditions
- Psychological Effects of Study Drug
- Interventions
- Lactose (inactive placebo), midomafetamine HCl
- Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 3
- States / cities
- Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
- Conditions
- Insomnia, Posttraumatic Stress Disorder
- Interventions
- suvorexant, placebo
- Drug · Other
- Lead sponsor
- Howard University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Exicorilant, Enzalutamide, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- AMG386 plus PLD, Placebo plus PLD
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more